Regional infrastructure tied to inappropriate breast, prostate cancer imaging
the ONA take:
Danil Makarov, MD, MHS, of the New York University School of Medicine and fellow researchers user SEER-Medicare data to identify patients with low-risk prostate or breast cancer.
While these two cancers affect different patient populations and therefore should not share an association in imaging, the researchers found a correlation between regional rates, leading them to believe that regional behaviors share common determinants.
They identified 9,2119 men with prostate cancer and 30,398 women with breast cancer in 84 hospital referral regions, with rates of inappropriate imaging found to be 44.4 percent and 41.8 percent, respectively.
Inappropriate prostate cancer imaging rates were associated with those of breast cancer rates at the hospital referral region level. This meant that a man with low-risk prostate cancer had a higher chance of undergoing inappropriate imaging if he lived in a hospital referral region with higher inappropriate breast cancer imaging levels.
“Our findings suggest that practice patterns may be a function of local propensities for health care utilization,” the authors stated. “This is a novel finding with great relevance to cancer policy.”
Regional infrastructure could contribute to inappropriate imaging in patients at risk for prostate and breast cancer.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|